The primary objective is to identify additional genetic loci associated with skin fluorescence in patients with type 1 diabetes Mellitus. Secondary we want to assess if the identified loci are also associated to HbA1C, or if alternative loci are…
ID
Source
Brief title
Condition
- Other condition
- Diabetic complications
Synonym
Health condition
identificeren van SNPs die geassocieerd zijn met huid fluorescentie
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary outcome variable for the Genomic-Wide Association Study (GWAS) will
be Skin Auto Fluorescence (SAF).
Secondary outcome
Association of SNPs with HbA1c
Background summary
As Eny et al showed, genetic variation contributes to variance in Skin
Fluorescence (SF) 1. However, not all of the familial correlation is explained
by the NAT2 locus. Therefore, in this study, we propose to identify additional
loci associated with SF, which we believe may improve future prediction of
diabetic complications based on SF screening, as well as improve the prediction
of type 2 diabetes risk in the general population
Study objective
The primary objective is to identify additional genetic loci associated with
skin fluorescence in patients with type 1 diabetes Mellitus. Secondary we want
to assess if the identified loci are also associated to HbA1C, or if
alternative loci are associated solely with HbA1c.
Study design
cross-sectional observational study
Study burden and risks
Patient burden will be limited, as the participation can be completed during
regular out-patient follow-up. Subjects will be asked to complete a
questionnaire to collect demographic data, a single blood test is required as
well as non-invasive measurement of SF and other Anthropometric.
No direct benefit from anticipation is expected for the subjects. However, this
study may increase current understanding and thereby aid future treatment
options, both for the patient as for the (diabetic) population in general. As
this involves an observational study, no risks are expected.
Wilhelminalaan 12
Alkmaar 1815 JD
NL
Wilhelminalaan 12
Alkmaar 1815 JD
NL
Listed location countries
Age
Inclusion criteria
Signed informed consent
Type 1 DM
Age * 18 years
Exclusion criteria
Subjects who lack mental capacity to make their own decision / subjects who have a legal-guardian for ongoing medical decisions (including but not limited to mental retardation, schizophrenia, bi-polar disorder, degenerative cognitive decline). ;Participant in life-line study.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL55763.094.15 |